Personalized cancer treatment and the myth of KRAS wild-type colon tumors

Discovery Medicine

Volumn 15, Issue 83, 2013, Pages 259-267

  Parsons, Barbara L ^a   Myers, Meagan B ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ANOXIA; ARTICLE; COLON TUMOR; DISEASE COURSE; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; HOMEOSTASIS; HUMAN; METABOLISM; METHODOLOGY; MUTATION; NUCLEOTIDE SEQUENCE; ONCOGENE RAS; PERSONALIZED MEDICINE; TUMOR CELL LINE;

ANOXIA; CELL LINE, TUMOR; COLONIC NEOPLASMS; DATABASES, GENETIC; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, RAS; GENETIC PREDISPOSITION TO DISEASE; HOMEOSTASIS; HUMANS; INDIVIDUALIZED MEDICINE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84886237663     PISSN: 15396509     EISSN: 19447930     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Al-Mulla F, Milner-White EJ, Going JJ, Birnie GD. Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression. J Pathol 187(4):433-438, 1999.
2. Alexander S, Friedl P. Cancer invasion and resistance: Interconnected processes of disease progression and therapy failure. Trends Mol Med 18(1):13-26, 2012.
3. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626-1634, 2008.
4. Amatu A, Sartore-Bianchi A, Bencardino K, Cassingena A, Venturini F, Giacobbe F, Pietrogiovanna L, Marrapese G, Gambaro A, Belotti A, Siena S. Is Codon 13 KRAS Mutation Biologically Different from Codon 12 Mutation?. Curr Colorectal Cancer Rep 8(4):272-276, 2012.
5. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 90(9):675-684, 1998.
6. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16(3):790-799, 2010.
7. Bando H, Yoshino T, Tsuchihara K, Ogasawara N, Fuse N, Kojima T, Tahara M, Kojima M, Kaneko K, Doi T, Ochiai A, Esumi H, Ohtsu A. KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab. Br J Cancer 105(3):403-406, 2011.
8. Baskin Y, Calibasi G, Canda E, Sarionulllu S, Yilmaz U. Pyrosequencing analysis for detection of KRAS mutations in colorectal cancer. In Vivo 25(3):519, 2011.
9. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17(3):320-329, 2011.
10. Blank PR, Moch H, Szucs TD, Schwenkglenks M. KRAS and BRAF mutation analysis in metastatic colorectal cancer: A cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 17(19):6338-6346, 2011.
11. Boldogh I, Hajas G, Aguilera-Aguirre L, Hegde ML, Radak Z, Bacsi A, Sur S, Hazra TK, Mitra S. Activation of Ras signaling pathway by 8-oxoguanine DNA glycosylase bound to its excision product, 8-oxoguanine. J Biol Chem 287(25):20769-20773, 2012.
12. Buhrman G, Kumar VS, Cirit M, Haugh JM, Mattos C. Allosteric modulation of Ras-GTP is linked to signal transduction through RAF kinase. J Biol Chem 286(5):3323-3331, 2011.
13. Carotenuto P, Roma C, Rachiglio AM, Tatangelo F, Pinto C, Ciardiello F, Nappi O, Iaffaioli V, Botti G, Normanno N. Detection of KRAS mutations in colorectal carcinoma patients with an integrated PCR/sequencing and real-time PCR approach. Pharmacogenomics 11(8):1169-1179, 2010.
14. Cespedes MV, Sancho FJ, Guerrero S, Parreno M, Casanova I, Pavon MA, Marcuello E, Trias M, Cascante M, Capella G, Mangues R. K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis 27(11):2190-2200, 2006.
15. Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol 6(12):2853-2868, 2008.
16. Davidson C, Zeringer E, Champion K, Gauthier M, Wang F, Boonyaratanakornkit J, Jones JR, Schreiber E. A simple method for improving the limit of detection for capillary electrophoresis DNA sequencing - A comparison of methodologies for KRAS variant detection. J Mol Diagn 14(6):740-741, 2012.
17. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 11(8):753-762, 2010a.
18. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304(16):1812-1820, 2010b.
19. Denicola GM, Tuveson DA. RAS in cellular transformation and senescence. Eur J Cancer 45(Suppl 1):211-216, 2009.
20. Diaz LA, Williams RT, Wu J, Kinde I, Hecht JR, Berlin J, Allen B, Bozic I, Reiter JG, Nowak MA, Kinzler KW, Oliner KS, Vogelstein B. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature doi:10.1038/nature11219, 2012.
21. Dieterle CP, Conzelmann M, Linnemann U, Berger MR. Detection of Isolated Tumor Cells by Polymerase Chain Reaction-Restriction Fragment Length Polymorphism for K-ras Mutations in Tissue Samples of 199 Colorectal Cancer Patients. Clin Cancer Res 10(2):641-650, 2004.
22. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 25(2):209-216, 2007.
23. Freeman DJ, Bush T, Ogbagabriel S, Belmontes B, Juan T, Plewa C, Van G, Johnson C, Radinsky R. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor. Mol Cancer Ther 8(6):1536-1546, 2009.
24. Freeman DJ, Juan T, Reiner M, Hecht JR, Meropol NJ, Berlin J, Mitchell E, Sarosi I, Radinsky R, Amado RG. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7(3):184-190, 2008.
25. Heinemann V, Douillard JY, Ducreux M, Peeters M. Targeted therapy in metastatic colorectal cancer - An example of personalised medicine in action. Cancer Treat Rev doi:10.1016/j.ctrv.2012.12.011, 2013.
26. Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 35(3):262-271, 2009.
27. Horne SD, Stevens JB, Abdallah BY, Liu G, Bremer SW, Ye CJ, Heng HH. Why imatinib remains an exception of cancer research. J Cell Physiol 228(4):665-670, 2013.
28. Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ, Ratain MJ, Topalian SL, Pardoll DM. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst 103(16):1222-1226, 2011.
29. Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, et al. Effect of KRAS oncogene substitutions on protein behavior: Implications for signaling and clinical outcome. J Natl Cancer Inst 104(3):228-239, 2012.
30. Kalliomaki TM, McCallum G, Lunt SJ, Wells PG, Hill RP. Analysis of the effects of exposure to acute hypoxia on oxidative lesions and tumour progression in a transgenic mouse breast cancer model. BMC Cancer 8(1):151, 2008.
31. Kizaka-Kondoh S, Tanaka S, Harada H, Hiraoka M. The HIF-1-active microenvironment: An environmental target for cancer therapy. Adv Drug Deliv Rev 61(7-8):623-632, 2009.
32. Kondo J, Endo H, Okuyama H, Ishikawa O, Iishi H, Tsujii M, Ohue M, Inoue M. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc Natl Acad Sci U S A 108(15):6235-6240, 2011.
33. Linardou H, Briasoulis E, Dahabreh IJ, Mountzios G, Papadimitriou C, Papadopoulos S, Bafaloukos D, Kosmidis P, Murray S. All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev 37(3):221-233, 2011.
34. Lu T, Finkel T. Free radicals and senescence. Exp Cell Res 314(9):1918-1922, 2008.
35. Mancuso A, Sollami R, Recine F, Cerbone L, Macciomei MC, Leone A. Patient with colorectal cancer with heterogeneous KRAS molecular status responding to cetuximab-based chemotherapy. J Clin Oncol 28(36):e756-e758, 2010.
36. McKinzie PB, Parsons BL. Detection of rare K-ras codon 12 mutations using allele-specific competitive blocker PCR. Mutat Res 517(1-2):209-220, 2002.
37. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486(7404):532-536, 2012.
38. Modest DP, Jung A, Moosmann N, Laubender RP, Giessen C, Schulz C, Haas M, Neumann J, Boeck S, Kirchner T, Heinemann V, Stintzing S. The influence of KRAS and BRAF mutations on the efficacy of cetuximab-based first-line therapy of metastatic colorectal cancer: An analysis of the AIO KRK-0104-trial. Int J Cancer 131(4):980-986, 2012.
39. Molinari F, Felicioni L, Buscarino M, De Dosso S, Buttitta F, Malatesta S, Movilia A, Luoni M, Boldorini R, Alabiso O, Girlando S, Soini B, Spitale A, Di Nicolantonio F, Saletti P, Crippa S, Mazzucchelli L, Marchetti A, Bardelli A, Frattini M. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res 17(14):4901-4914, 2011.
40. Ogino S, Kawasaki T, Brahmandam M, Yan L, Cantor M, Nangyal C, Mino-Kenudson M, Lauwers GY, Loda M, Fuchs CS. Sensitive sequencing method for KRAS mutation detection by pyrosequencing. J Mol Diagn 7(3):413-421, 2005.
41. Parsons BL. Many different tumor types have polyclonal tumor origin: Evidence and implications. Mutat Res 659(3):232-247, 2008.
42. Parsons BL, Heflich RH. Genotypic selection methods for the direct analysis of point mutations. Mutat Res 387(2):97-121, 1997.
43. Parsons BL, Marchant-Miros KE, Delongchamp RR, Verkler TL, Patterson TA, McKinzie PB, Kim LT. ACB-PCR quantification of K-RAS codon 12 GAT and GTT mutant fraction in colon tumor and non-tumor tissue. Cancer Invest 28(4):364-375, 2010a.
44. Parsons BL, Myers MB. KRAS mutant tumor subpopulations can subvert durable responses to personalized cancer treatments. Pers Med 10(2):191-199, 2013.
45. Parsons BL, Myers MB, Meng F, Wang Y, McKinzie PB. Oncomutations as biomarkers of cancer risk. Environ Mol Mutagen 51(8-9):836-850, 2010b.
46. Pentheroudakis G, Kotoula V, De Roock W, Kouvatseas G, Papakostas P, Makatsoris T, Papamichael D, Xanthakis I, Sgouros J, Televantou D, Kafiri G, Tsamandas AC, Razis E, Galani E, Bafaloukos D, Efstratiou I, Bompolaki I, Pectasides D, Pavlidis N, Tejpar S, et al. Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: Interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer 13:49, 2013.
47. Prior IA, Lewis PD, Mattos C. A comprehensive survey of ras mutations in cancer. Cancer Res 72(10):2457-2467, 2012.
48. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Saavedra E, Moreno-Sanchez R. The causes of cancer revisited: "Mitochondrial malignancy" and ROS-induced oncogenic transformation - Why mitochondria are targets for cancer therapy. Mol Aspects Med 31(2):145-170, 2010.
49. Richman SD, Chambers P, Seymour MT, Daly C, Grant S, Hemmings G, Quirke P. Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing. Anal Cell Path 34(1-2):61-66, 2011.
50. Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N, Jacks T. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A 108(21):8773-8778, 2011.
51. Thirlwell C, Will OC, Domingo E, Graham TA, McDonald SA, Oukrif D, Jeffrey R, Gorman M, Rodriguez-Justo M, Chin-Aleong J, Clark SK, Novelli MR, Jankowski JA, Wright NA, Tomlinson IP, Leedham SJ. Clonality Assessment and Clonal Ordering of Individual Neoplastic Crypts Shows Polyclonality of Colorectal Adenomas. Gastroenterology 138(4):1441-1454.e7, 2010.
52. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99(19):1441-1454, 2007.
53. Xu W, Trepel J, Neckers L. Ras, ROS and proteotoxic stress: A delicate balance. Cancer Cell 20(3):281-282, 2011.
54. Young A, Lou D, McCormick F. Oncogenic and wild-type ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov 3(1):112-123, 2013.
55. Zeki SS, Graham TA, Wright NA. Stem cells and their implications for colorectal cancer. Nat Rev Gastroenterol Hepatol 8(2):90-100, 2011.